Engflag

Avicel

Quick links to important sections

Avicel

Avicel_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Avicel

Quick Facts

Property Description
Active Ingredient Cellulose (Microcrystalline Cellulose)
Form Powder (Used in Tablets and Capsules)
Pharmacological Class Pharmaceutical Excipient / Inactive Ingredient
General Purpose Binder, Diluent, Disintegrant
Origin Natural Polymer (Derived from plant material)

What is Avicel and How is it Classified?

Avicel is the trade name for Microcrystalline Cellulose (MCC), an official Pharmaceutical Excipient classified as an Inactive Ingredient. This substance does not possess pharmacological activity; instead, it performs a crucial structural function in the manufacturing of various solid medications. Chemically, MCC is a natural polymer derived from Cellulose, obtained from fibrous plant material through a rigorous process of purification and controlled partial depolymerization. This refinement yields a Standardized Grade material, composed primarily of linear beta-(1 ightarrow4)-linked D-glucose units, providing consistent quality essential for reliable pharmaceutical formulation across products.

Avicel's Functional Role and Physical Form

Avicel is used in medicine as a fine, white, odorless powder, serving as a Pharmaceutical Auxiliary that creates solid dosage forms, primarily tablets and capsules, intended for oral administration. Its unique advantage lies in its multifunctionality: it acts as a diluent (bulking agent), a powerful binder or compression aid that gives the tablet its structural integrity, and a disintegrant. Microcrystalline Cellulose is utilized for its superior direct compressibility and ability to function as a multi-functional excipient. This physical property is critical for forming strong tablets without requiring complex manufacturing steps, which supports industrial stability and formulation consistency.

Why is Microcrystalline Cellulose Used in Medicine?

The primary purpose of incorporating MCC is to guarantee the quality, stability, and reliable performance of the finished medication, as it is entirely inert and non-reactive within the body. Its physical properties are leveraged to stabilize the active ingredients and ensure their timely availability: MCC acts as a disintegrant by rapidly absorbing water after ingestion, causing the tablet to swell and break apart, which initiates the precise release of the therapeutic agent for absorption. As an inactive component, Avicel is neither absorbed nor metabolized by the human body; it passes through the digestive system without exerting a direct physiological effect.

What side effects are possible with Avicel?

Possible Side Effects and Safety Information

Avicel is the brand name for Microcrystalline Cellulose (MCC), an inert excipient. It is not an active drug ingredient and is primarily used as a filler or binder in medicines. Because it is inert and passes through the body undigested, its official safety profile, as documented by regulatory bodies such as the FDA and EMA, is focused on its physical properties and mechanical risks, rather than systemic drug-like side effects.

Safety Profile Summary

Safety Domain Regulatory Documentation Point
Classification Classified as an Inactive Ingredient or Generally Recognized As Safe (GRAS) at common dose levels.
System-Organ Class Primarily involves Gastrointestinal disorders due to its bulk-forming nature.
Serious Adverse Reaction Potential for Gastrointestinal Obstruction (intestinal blockage) is documented, especially with large, unhydrated intake.

Safety Considerations

  • Population-Specific Warnings: Safety information advises caution for individuals with pre-existing conditions that affect the digestive tract, such as difficulty swallowing (dysphagia) or internal strictures, due to the material's bulk-forming nature.
  • Dose-Related Effects: Adverse effects like diarrhea, bloating, or flatulence are possible, but typically only at high oral intake levels, far exceeding the small quantity used in a single tablet or capsule.
  • Restrictions: Regulatory safety measures restrict the use of MCC/Avicel to certain routes of administration, such as oral and topical, unless specifically certified for use in parenteral (injectable) products.

The regulatory safety structure for Avicel confirms that its risks are primarily non-systemic and mechanical, reflecting its role as a high-bulk, non-absorbable component of a medicinal product.

Overdose and Emergency Response

The official regulatory profile for an overdose involving Avicel, or Microcrystalline Cellulose, is strictly defined by its classification as an inert, non-systemically absorbed pharmaceutical excipient. This substance lacks pharmacological activity, meaning the primary concern is not systemic toxicity but rather the mechanical risk of obstruction.

Documented overdose presentations focus on bulk effects. These may include a laxative effect from the increase in dietary mass when excessive quantities are consumed. The most serious potential outcome is the risk of choking, which may occur if the material is ingested without adequate fluid, causing it to swell and potentially block the throat or esophagus.

Immediate medical attention is officially mandated if specific symptoms of potential obstruction occur. Urgent medical help must be sought for signs including chest pain, vomiting, or difficulty in swallowing or breathing. In such events, individuals must immediately contact a Poison Control Center or seek emergency services.

Management described in regulatory documentation centers on supportive measures. Given the inert nature of the substance, no specific pharmacological antidote is known or available. Overdose procedures involve initiating careful observation and providing symptomatic treatment and supportive care.

Therapeutic Uses of Avicel

Avicel (Microcrystalline Cellulose) is strictly an inactive pharmaceutical excipient that plays a role in supporting the reliable delivery and quality of the active drug. Its therapeutic contribution supports the active medication in performing as intended to address symptomatic discomfort. Microcrystalline Cellulose is recognized as a component used in approved drug products, consistent with its foundational role in drug formulation.

Supporting Reliable Relief for Episodic Symptoms and Chronic Management

Avicel's functional consistency is relevant in situations involving symptoms associated with acute or episodic changes where patients may benefit from timely therapeutic availability, and it provides the necessary structural foundation for medications commonly used in long-term management and chronic conditions. This is applicable across clinical settings that involve acute or unstable symptom patterns and conditions characterized by periods of heightened symptoms, helping to address symptoms that interfere with daily functioning or create noticeable physiological strain.

“The consistent physical properties of the excipient are necessary for achieving the standardized performance relevant to effective patient treatment.”

This structural support contributes to improved comfort during periods of heightened symptoms by supporting consistent therapeutic action and assisting with maintaining functional stability during symptomatic periods.

Quick Fact: Relief for Symptomatic Burden

Property Description
Primary Functional Benefit Plays a role in supporting uniform delivery of the active drug
Target Clinical Scenarios Oral Maintenance Therapy, Fast-Acting Symptom Relief
Contribution to Patient Contributes to easing the overall symptom load and supports comfort
Applicable Symptom Domains Acute, Episodic, and Chronic manifestations

Regulatory References

  1. U.S. Food and Drug Administration (FDA) Inactive Ingredient Database

Eligibility and Restrictions for Use

Avicel (Microcrystalline Cellulose) is classified by regulatory authorities as an inactive pharmaceutical excipient that is not systemically absorbed into the body and does not possess pharmacological activity. Consequently, its official eligibility profile is defined by a strong safety record and the absence of most restrictions found in active drug substances.

Eligibility Scope

Scope Item Official Regulatory Statement
Populations for whom use is allowed Generally established as acceptable for use in pediatric, adult, and older adult populations in solid oral dosage forms.
Populations for whom use is contraindicated Patients with known hypersensitivity or documented allergic reaction to Microcrystalline Cellulose or any cellulose-derived component.
Condition-specific eligibility rules None documented. No limitations are specified based on organ function, such as hepatic impairment or renal impairment.
Pregnancy and lactation eligibility None documented. No official restrictions or prohibitions are mandated by regulatory agencies regarding use during pregnancy or lactation.

Eligibility Classification (High-Level)

Eligibility severity classification (as defined in official documents): Absolute Contraindication (Hypersensitivity) is the sole exclusion.

Regulatory basis: Classification is based on the consensus regulatory status of Microcrystalline Cellulose as an inert, non-systemically absorbed pharmaceutical excipient.

Connection to the overall eligibility profile: Official regulatory documents define the eligibility profile for Avicel almost entirely by the absence of restrictions due to its role as an inert pharmaceutical excipient. Eligibility is only precluded in the instance of a documented allergic reaction to the substance itself, which is the sole, absolute contraindication listed in regulatory documentation.

What should I know about interactions with other medicines?

Microcrystalline Cellulose (Avicel) is classified in regulatory documents as an inactive pharmaceutical excipient, meaning it does not possess inherent pharmacological activity. This designation is critical to its official interaction profile, which is defined by the absence of systemic drug-drug interactions in government-approved prescribing information.

Official Interaction Profile

Category Official Regulatory Status
Medicinal Product Categories None documented.
Pharmacokinetic Interactions None documented.
Timing-based Rules None documented.
Restrictions None documented.

Regulatory authorities, including the U.S. Food and Drug Administration and the European Medicines Agency, confirm that Microcrystalline Cellulose is not absorbed into the bloodstream. This lack of systemic exposure results in no formally documented pharmacokinetic interactions, such as those mediated by CYP enzymes or drug transport proteins (P-gp, OATP). Similarly, the official profile confirms the absence of documented pharmacodynamic interactions, as Avicel does not exert additive or synergistic effects on co-administered medicines. Consequently, government regulatory labels list no explicitly contraindicated combinations, no mandatory timing separation requirements with food or other medicines, and no population-specific interaction considerations (e.g., related to hepatic or renal function). The official interaction profile is therefore characterized by regulatory silence on systemic drug-drug conflicts, reflecting the substance's chemically inert nature and its confirmed role as a structural, non-active component in medication formulations.

Mechanism of Action

Essential Role in Tablet Structural Integrity

Avicel's primary mechanism involves material science: it functions as a high-performance binder by using plastic deformation to form strong internal hydrogen bonds between particles during manufacturing. This creates a stable, high-strength tablet matrix, which is a necessary first step that ensures the precise dose of the Active Pharmaceutical Ingredient (API) is preserved and delivered intact to the gastrointestinal tract.

Mechanism of Rapid Drug Dispersal Kinetics

The subsequent mechanism is governed by physicochemical kinetics within the GI lumen. Due to its inherent hydrophilicity, Avicel rapidly draws in water via capillary action. This absorption generates high internal pressure that causes the tablet to swell and quickly rupture (disintegration), accelerating the dissolution rate of the API. This physical dispersal is the prerequisite that enables the drug molecules to be made available for absorption into the bloodstream.

Physicochemical Constraint on Onset

The overall function is critically constrained by the grade and particle size of the MCC, as well as the compaction force used during processing. These formulation variables directly regulate the speed and efficiency of the fluid absorption and subsequent disintegration mechanism. The resulting physiological effect is the controlled rate of systemic drug availability, as the API cannot begin its intended molecular action until this physical process is complete.

Dosage and Administration Information

How Avicel is Used: Official Administration Guidelines

Avicel, the trade name for Microcrystalline Cellulose (MCC), is an inactive pharmaceutical excipient—a component used in manufacturing, not an active drug with a clinical dose. Therefore, its official use is defined by formulation standards rather than patient-specific instructions, ensuring the quality and reliable performance of the final medication.

Official Administration and Formulation Principles

Usage Entity Official Regulatory Principle / Description
Route of Administration Primarily Oral, incorporated into finished dosage forms like tablets and capsules. It is also documented for use in Topical and Sublingual (under-the-tongue) products.
Formulation Limits MCC does not have a clinical dose. Its quantity is a formulation specification that must not exceed the maximum allowable amount per dosage unit.
Timing and Frequency N/A (Excipient). The frequency and timing (e.g., with or without food) are dictated by the active drug in the final product. MCC’s structural role guarantees that the physical form supports the necessary release schedule.
Integrity and Handling MCC is essential for ensuring the final drug product meets standards for structural integrity (hardness and stability). This is why certain tablets containing MCC may be officially labeled as non-crushable to preserve the intended drug release mechanism.

Connection to the Overall Use Protocol

These official instructions define Avicel's use as a fundamental structural component of medications. Its regulated inclusion ensures the final oral product is consistently available to the patient, reliably breaks apart after ingestion, and maintains its physical stability throughout its shelf life, consistent with the active drug's labeled instructions.

Recent Clinical Evidence

Microcrystalline Cellulose (Avicel) in Clinical Research

Avicel is a common trade name for microcrystalline cellulose (MCC), which is an inactive ingredient (excipient) widely used in pharmaceutical and food products. MCC itself does not possess active therapeutic properties; consequently, clinical trials do not study Avicel as a drug treatment.

Instead, recent clinical evidence focuses on two primary areas:

  1. Use as a Placebo: MCC is frequently employed as an inert placebo in randomized, double-blind clinical trials to test the effectiveness of active drugs. Its safety profile, chemical inertness, and ability to be formulated to look identical to an active medication make it ideal for creating control groups in research across various conditions, including chronic pain, metabolic disorders, and neurological conditions.

  2. Role in Drug Formulation: Extensive research centers on the utility of MCC as a pharmaceutical excipient. Studies evaluate its mechanical properties and how they impact drug performance, specifically in solid oral dosage forms like tablets and capsules. Findings confirm its critical roles as a binder to ensure tablet strength and a disintegrant to help the tablet break apart efficiently in the digestive tract, which is necessary for the active drug's absorption. Research continually explores new formulations where MCC is co-processed with other excipients to improve tableting efficiency and consistency for complex or high-dose active pharmaceutical ingredients.

Frequently Asked Questions (FAQ)

Common questions about Avicel (FAQ)

Q: Can Avicel cause any allergic reactions?

Official eligibility documents confirm that a known hypersensitivity or documented allergic reaction to Microcrystalline Cellulose is the sole absolute contraindication for its use. This restriction means that while such reactions are possible, they are the primary regulatory exclusion regarding the use of a medicine containing Avicel.

Q: Does Avicel affect how the body absorbs the active drug?

Microcrystalline Cellulose (Avicel) is classified as an inactive ingredient, but it plays a crucial physical role in how the active drug is delivered. Official mechanism information states that Avicel helps the tablet break apart quickly after being swallowed. This process, known as disintegration, accelerates the rate at which the active drug dissolves, which is the physical step that enables the active drug to be made available for the body's absorption.

Q: Can Avicel cause digestive issues like bloating or gas?

According to official safety information, mild gastrointestinal issues such as bloating and flatulence are possible side effects of Microcrystalline Cellulose. However, these effects typically occur only at high oral intake levels that far exceed the amount found in a single tablet or capsule.

Q: Can taking too many tablets with Avicel cause a problem?

Official safety information documents the potential for Gastrointestinal Obstruction (an intestinal blockage) associated with the ingestion of large, unhydrated quantities of Microcrystalline Cellulose. This is due to its high-bulk nature and tendency to swell.

Q: Is it possible to be sensitive to Avicel?

Yes, official eligibility documents confirm that a known hypersensitivity (severe sensitivity or allergic reaction) to Microcrystalline Cellulose is the sole absolute contraindication for its use. This specific restriction is based on official safety standards.

Q: What is the maximum amount of Avicel considered acceptable in a daily intake?

The amount of Avicel used in medication is not a clinical dose but a formulation specification. Official regulatory databases, such as the FDA's Inactive Ingredient Database, specify the maximum allowable amount that can be included in each dosage unit to ensure safety and quality standards are met.

Q: Does Avicel affect drug stability or shelf life?

Yes, official administration guidelines state that Microcrystalline Cellulose is essential for the physical stability and structural integrity of the medication. This role helps guarantee that the tablet or capsule remains intact and consistent throughout its intended shelf life.

Q: Why is Avicel included in so many different kinds of pills?

Microcrystalline Cellulose is widely used because regulatory bodies and official product standards recognize it as a multifunctional excipient. It can act as a binder to hold the tablet together, a filler to increase bulk, and a disintegrant to help the pill break apart, making it valuable for many different drug manufacturing processes.

Q: Does Avicel have any uses besides being a filler in tablets?

Beyond oral tablets and capsules, official documents note that Microcrystalline Cellulose is documented for use in Topical (on the skin) and Sublingual (under the tongue) products in addition to oral forms. Furthermore, regulatory bodies classify it as a Generally Recognized As Safe (GRAS) food additive for use as a stabilizer or texturizer in food products.

Q: Is Avicel considered safe for everyday use in supplements?

Microcrystalline Cellulose is classified as a Generally Recognized As Safe (GRAS) food additive and is also listed in the FDA Inactive Ingredient Database for medications. This classification supports its widespread acceptability for general daily consumption within established limits in both supplements and pharmaceutical products.

Q: Is there a difference between Avicel and other common tablet fillers?

Official formulation references characterize Microcrystalline Cellulose as highly valued because of its superior direct compressibility and its ability to function effectively as a multi-functional excipient. These properties allow it to form strong, high-quality tablets more efficiently than many other single-function fillers.

Q: Can Avicel be used by people with a cellulose allergy?

Official restrictions specify that a person with a documented allergy to Microcrystalline Cellulose or any cellulose-derived component should not use medications that contain it. The contraindication rule applies broadly to reactions involving cellulose-based substances.

Q: What is Avicel made from?

Avicel is the trade name for Microcrystalline Cellulose (MCC), which is an official pharmaceutical excipient. It is described in monographs as a natural polymer derived from fibrous plant material (cellulose) that has been purified and subjected to a controlled processing technique.

Q: Is Avicel found in liquid medicines, or just solids?

While commonly used to create solid forms like tablets and capsules, official regulatory documents also outline the use of Microcrystalline Cellulose in non-solid forms. It can be formulated into suspensions and semi-solid syrups, where it acts as a thickening agent and viscosity stabilizer.

Q: Does Avicel interact with common over-the-counter pain relievers?

No, official interaction profiles confirm that Microcrystalline Cellulose is not systemically absorbed into the bloodstream. This inert nature means it has no formally documented pharmacokinetic or pharmacodynamic interactions with other medicinal product categories, including over-the-counter pain relievers.

Q: Are there different grades or types of Avicel used in medicines?

Yes, official formulation references confirm that Microcrystalline Cellulose is available in multiple standardized grades. These grades vary primarily in particle size and density, allowing manufacturers to select the best type to meet the specific needs of different drug formulations and processes.

Q: Has the FDA (or other major agencies) approved Avicel for use in medications?

Microcrystalline Cellulose is included and regulated by major government health agencies globally. For instance, the FDA lists it in its Inactive Ingredient Database, and it must adhere to international quality standards set by bodies like the European Medicines Agency (EMA), confirming its acceptability for use in pharmaceutical products.

Q: Is it normal to see Avicel listed in both prescription and non-prescription products?

Yes, as a general-purpose, non-active excipient, Microcrystalline Cellulose is officially used across both prescription (Rx) and non-prescription (Over-the-Counter) medicinal products. Its function as a structural component is required regardless of the active drug's legal classification.

Q: How does the manufacturing process of Avicel affect its safety?

The manufacturing process must adhere to strict regulatory quality and safety standards for pharmaceutical use. Recent regulatory focus on potential impurities has led manufacturers to develop low-nitrite grades of Microcrystalline Cellulose to mitigate the potential risk of N-nitrosamine formation in the finished drug product.

Q: Can Avicel impact the effectiveness of hormonal birth control?

Official interaction profiles confirm Microcrystalline Cellulose is not systemically absorbed and has no formally documented pharmacokinetic or pharmacodynamic interactions with any medicinal product categories. Therefore, it has no documented systemic effect on the effectiveness of hormonal birth control.

Q: Is Avicel considered a 'natural' ingredient?

Regulatory documents describe Microcrystalline Cellulose as a natural polymer because it is derived from cellulose found in fibrous plant material. This process of purification and refinement establishes its use as a standardized, regulated ingredient.

Q: Does Avicel accumulate in the body over time?

Official regulatory profiles confirm that Microcrystalline Cellulose is not absorbed or metabolized by the body after ingestion. As an inert ingredient, it does not accumulate and instead passes through the digestive system undigested.

Q: Why is Avicel sometimes listed by a different name on the label?

Avicel is a widely recognized trade name for the substance. However, official regulatory and pharmacopoeial documents most commonly recognize it by its chemical name, Microcrystalline Cellulose (MCC), and may list it under that name on product labels.

Q: Can Avicel be found in supplements or vitamins?

Yes, Microcrystalline Cellulose is commonly found in supplements and vitamins. Its use is supported by its classification as Generally Recognized As Safe (GRAS) by the FDA and its official function as a high-performance binder and filler in solid dosage forms.

Q: What is the difference between Avicel and powdered cellulose?

Microcrystalline Cellulose (Avicel) is a specific Standardized Grade of cellulose used in pharmaceuticals. It is manufactured using a controlled process of purification and partial depolymerization of natural cellulose, making it a highly refined material that is chemically distinct from less controlled powdered cellulose.

Q: Is the Avicel content regulated in different countries in the same way?

Yes, the quality and content of Microcrystalline Cellulose are regulated globally. It must adhere to established international standards and monographs, such as the United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.), ensuring a consistent level of quality and safety across different countries.

Q: Does Avicel interact with supplements like fish oil or multivitamins?

Official interaction profiles confirm Microcrystalline Cellulose is not systemically absorbed and has no formally documented pharmacokinetic or pharmacodynamic interactions with other medicinal product categories. This rule of non-interaction extends to supplements such as fish oil or multivitamins.

How should Avicel be stored and disposed of?

Storage and Disposal Requirements for Avicel

Avicel (Microcrystalline Cellulose), as a pharmaceutical excipient, must be stored under specific regulatory conditions to maintain its quality and stability.

Storage Conditions

The product must be stored in a cool, dry, and well-ventilated place at temperatures not exceeding 30 C. Containers must be tightly closed to protect the material from moisture and humidity and kept out of direct sunlight. Finished medicinal products containing Avicel must be stored out of the sight and reach of children.

Handling and Disposal

Handling requires that the material be kept away from heat and sources of ignition, and dust generation should be avoided due to potential combustion hazard. Disposal of any unused Avicel or resulting waste material must be conducted in accordance with local regulations, often classifying the material as special waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Avicel found in:

A-Z Index: